ID25824A - Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali - Google Patents

Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali

Info

Publication number
ID25824A
ID25824A IDP20001006A ID20001006A ID25824A ID 25824 A ID25824 A ID 25824A ID P20001006 A IDP20001006 A ID P20001006A ID 20001006 A ID20001006 A ID 20001006A ID 25824 A ID25824 A ID 25824A
Authority
ID
Indonesia
Prior art keywords
tolterodins
provide controlled
therapeutic formulation
therapeutic
formulation
Prior art date
Application number
IDP20001006A
Other languages
English (en)
Indonesian (id)
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Strombom
Bo Kreilgard
L Orup Jacobsen
Ulla Hoeck
Helle Kristensen
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID25824(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of ID25824A publication Critical patent/ID25824A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IDP20001006A 1998-08-27 1999-08-26 Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali ID25824A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation

Publications (1)

Publication Number Publication Date
ID25824A true ID25824A (id) 2000-11-09

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP20001006A ID25824A (id) 1998-08-27 1999-08-26 Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali

Country Status (31)

Country Link
US (1) US6770295B1 (no)
EP (2) EP2153825A1 (no)
CN (1) CN1239152C (no)
AP (1) AP1529A (no)
AR (1) AR029311A1 (no)
AT (1) ATE487471T1 (no)
AU (1) AU745190B2 (no)
BG (1) BG65168B1 (no)
CA (1) CA2311755C (no)
CY (1) CY1111088T1 (no)
CZ (1) CZ302630B6 (no)
DE (1) DE69942928D1 (no)
DK (1) DK1039882T3 (no)
EA (1) EA002720B1 (no)
GE (1) GEP20043354B (no)
HK (1) HK1034664A1 (no)
HU (1) HUP0100437A3 (no)
ID (1) ID25824A (no)
IL (1) IL136294A (no)
IS (1) IS2976B (no)
ME (1) ME00850B (no)
MY (1) MY127946A (no)
NO (1) NO329830B1 (no)
NZ (1) NZ504618A (no)
OA (1) OA11636A (no)
PT (1) PT1039882E (no)
SI (1) SI1039882T1 (no)
SK (1) SK287111B6 (no)
TR (1) TR200001998T1 (no)
UA (1) UA72882C2 (no)
WO (1) WO2000012069A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
SK6412002A3 (en) * 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CA2514022C (en) * 2003-01-22 2010-07-13 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
US7410978B2 (en) 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
JP4771956B2 (ja) 2003-11-04 2011-09-14 スパーナス ファーマシューティカルズ インコーポレイテッド バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2604052C (en) * 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
JP5869745B2 (ja) 2006-02-03 2016-02-24 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療
US20070248670A1 (en) * 2006-04-21 2007-10-25 Van Den Heuvel Dennie J M Tolterodine beads
EP3659608A1 (en) 2006-06-21 2020-06-03 Opko Ireland Global Holdings, Ltd. Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
ES2956794T3 (es) 2007-04-25 2023-12-28 Eirgen Pharma Ltd Liberación controlada de 25-hidroxivitamina D
EP3335712A1 (en) 2007-04-25 2018-06-20 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
EP2173329A1 (en) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
KR102125424B1 (ko) 2010-03-29 2020-06-22 사이토크로마 인코포레이티드 부갑상선 수준을 낮추기 위한 방법 및 조성물
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20130195957A1 (en) * 2010-08-03 2013-08-01 Hisamitsu Pharmaceutical Co., Inc. Patch and method for enhancing adhesion force of the same
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
BR112018069727A2 (pt) 2016-03-28 2019-02-05 Opko Ireland Global Holdings Ltd métodos de tratamento com vitamina d

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
WO1993023025A1 (en) * 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
EP0927034A1 (en) * 1996-09-19 1999-07-07 American Home Products Corporation Method of treating urinary incontinence

Also Published As

Publication number Publication date
CA2311755A1 (en) 2000-03-09
MY127946A (en) 2007-01-31
IS2976B (is) 2017-07-15
BG65168B1 (bg) 2007-05-31
NO20002977D0 (no) 2000-06-09
HK1034664A1 (en) 2001-11-02
EP2153825A1 (en) 2010-02-17
GEP20043354B (en) 2004-04-13
CZ302630B6 (cs) 2011-08-10
AR029311A1 (es) 2003-06-25
PT1039882E (pt) 2011-01-03
BG104476A (en) 2000-12-29
CN1287484A (zh) 2001-03-14
WO2000012069A1 (en) 2000-03-09
CY1111088T1 (el) 2015-06-11
SI1039882T1 (sl) 2011-01-31
AU5891899A (en) 2000-03-21
US6770295B1 (en) 2004-08-03
EA200000468A1 (ru) 2000-12-25
NO329830B1 (no) 2011-01-03
CZ20001924A3 (cs) 2001-04-11
IL136294A0 (en) 2001-05-20
AP1529A (en) 2006-01-03
EA002720B1 (ru) 2002-08-29
AP2000001823A0 (en) 2000-06-30
DK1039882T3 (da) 2011-01-24
OA11636A (en) 2004-09-03
HUP0100437A2 (hu) 2002-05-29
NZ504618A (en) 2002-09-27
SK7492000A3 (en) 2001-02-12
EP1039882A1 (en) 2000-10-04
ME00850B (me) 2008-08-07
CN1239152C (zh) 2006-02-01
EP1039882B1 (en) 2010-11-10
ATE487471T1 (de) 2010-11-15
DE69942928D1 (de) 2010-12-23
NO20002977L (no) 2000-06-09
SK287111B6 (sk) 2009-12-07
TR200001998T1 (tr) 2001-01-22
UA72882C2 (uk) 2005-05-16
HUP0100437A3 (en) 2002-08-28
CA2311755C (en) 2010-03-23
IL136294A (en) 2004-02-08
IS5537A (is) 2000-06-15
AU745190B2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
ID25824A (id) Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
ID22878A (id) Komposisi aktif secara terapi
ID19875A (id) Poliolefin yang dimodifikasi menurut reologi
ID22939A (id) Formulasi-formulasi farmasi yang mengandung vorikonozal
ID21236A (id) Penggunaan komposisi bioaktif yang dikapsulkan
ID25476A (id) Komposisi-komposisi yang tidak dapat larut untuk mengontrol glukosa darah
ID27841A (id) Turunan-turunan biaril terapeutik
ID26330A (id) Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi
DE60024988D1 (de) Herstellung von therapeutischem mikroschaum
ID28962A (id) Komposisi poliolefin yang tahan benturan
ID20837A (id) Mikrokapsul dengan laju pelepasan yang mudah disesuaikan
ID29468A (id) Komposisi farmasi yang stabil dalam bentuk liofil
ID26317A (id) Formulasi pelepasan yang diperpanjang
NO20022692D0 (no) Terapeutiske midler
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
ID24259A (id) Formulasi obat yang memiliki pelepasan senyawa aktif terkontrol
ID26474A (id) Komposisi kosmetik topikal yang mengandung benzaldoksim
ID29792A (id) Formulasi lepas terkendali untuk mengobati corp
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
ID24617A (id) Komposisi kosmetik yang mengkondisikan kulit
ID24060A (id) Pengolahan kulit hewan yang ditingkatkan
ID27096A (id) Komposisi farmasi yang baru